Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy inadvanced nonsquamous non–small cell lung cancer (WJOG 5910L): An open-label, randomized, phase II trial.
2015 ◽
Vol 33
(15_suppl)
◽
pp. 8056-8056
Keyword(s):
2012 ◽
Vol 7
(1)
◽
pp. 196-202
◽
Keyword(s):
2010 ◽
Vol 28
(15_suppl)
◽
pp. 7583-7583
Keyword(s):
2011 ◽
Vol 6
(1)
◽
pp. 109-114
◽
Keyword(s):
2011 ◽
Vol 6
(9)
◽
pp. 1569-1577
◽
Keyword(s):
2010 ◽
Vol 28
(15_suppl)
◽
pp. 7593-7593
Keyword(s):